Abstract P6-13-01: Triplet therapy with ribociclib, everolimus, and exemestane in women with HR+/HER2– advanced breast cancer | Citedby Results | Cancer Research | American Association for Cancer Research

Skip to Main Content

Skip Nav Destination

Abstract P6-13-01: Triplet therapy with ribociclib, everolimus, and exemestane in women with HR+/HER2– advanced breast cancer

Cancer Res (2016) 76 (4_Supplement): P6-13-01.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Effectiveness of Changing the Class of Molecularly Targeted Agent after Disease Progression during Initial Molecularly Targeted Therapy for Luminal Advanced/Metastatic Breast Cancer

Satoko Nakano
Akemi Mibu
Shunsuke Kato
Shigeo Yamaguchi
Yuna Suzuki
Kaoru Tanimura
Masataka Sano

Journal of Nippon Medical School (2023) 90 (2): 179.

A Phase I and Surgical Study of Ribociclib and Everolimus in Children with Recurrent or Refractory Malignant Brain Tumors: A Pediatric Brain Tumor Consortium Study

Mariko D. DeWire
Christine Fuller
Olivia Campagne
Tong Lin
Haitao Pan
Tina Young Poussaint
Patricia A. Baxter
Eugene I. Hwang
Andrew Bukowinski
Kathleen Dorris
Lindsey Hoffman
Angela J. Waanders
Matthias A. Karajannis
Clinton F. Stewart
Arzu Onar-Thomas
Maryam Fouladi
Ira J. Dunkel

Clinical Cancer Research (2021) 27 (9): 2442.

Emerging data and future directions for CDK4/6 inhibitor treatment of patients with hormone receptor positive HER2‐non‐amplified metastatic breast cancer

Elgene Lim
Jane Beith
Frances Boyle
Richard de Boer
Rina Hui
Nicole McCarthy
Andrew Redfern
Theresa Wade
Natasha Woodward

Asia-Pacific Journal of Clinical Oncology (2018) 14 (S4): 12.

CDK4/6 inhibitors in HER2-positive breast cancer

Silvia Paola Corona
Andrea Ravelli
Daniele Cretella
Maria Rosa Cappelletti
Laura Zanotti
Martina Dester
Angela Gobbi
Pier Giorgio Petronini
Daniele Generali

Critical Reviews in Oncology/Hematology (2017) 112: 208.

Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors

Debu Tripathy
Aditya Bardia
William R. Sellers

Clinical Cancer Research (2017) 23 (13): 3251.

CDK4/6 Inhibitors in Cancer Therapy: A Novel Treatement Strategy for Bladder Cancer

Qi Pan
Anuja Sathe
Peter C. Black
Peter J. Goebell
Ashish M. Kamat
Bernd Schmitz-Draeger
Roman Nawroth

Bladder Cancer (2017) 3 (2): 79.

New agents for the management of resistant metastatic breast cancer

Jesus Anampa
Joseph A. Sparano

Expert Opinion on Pharmacotherapy (2017) 18 (17): 1815.

Progress with palbociclib in breast cancer: latest evidence and clinical considerations

Andrea Rocca
Alessio Schirone
Roberta Maltoni
Sara Bravaccini
Lorenzo Cecconetto
Alberto Farolfi
Giuseppe Bronte
Daniele Andreis

Therapeutic Advances in Medical Oncology (2017) 9 (2): 83.

Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib

Dorota Kwapisz

Breast Cancer Research and Treatment (2017) 166 (1): 41.

Consequences of the Convergence of Multiple Alternate Pathways on the Estrogen Receptor in the Treatment of Metastatic Breast Cancer

Stefan Glück

Clinical Breast Cancer (2017) 17 (2): 79.

Ribociclib: First Global Approval

Yahiya Y. Syed

Drugs (2017) 77 (7): 799.

Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer

Romualdo Barroso-Sousa
Geoffrey I. Shapiro
Sara M. Tolaney

Breast Care (2016) 11 (3): 167.

Specific CDK4/6 inhibition in breast cancer: a systematic review of current clinical evidence

Anne Polk
Ida Lykke Kolmos
Iben Kümler
Dorte Lisbeth Nielsen

ESMO Open (2016) 1 (6): e000093.

Targeting CDK4/6 in patients with cancer

Erika Hamilton
Jeffrey R. Infante

Cancer Treatment Reviews (2016) 45: 129.